OMER · Omeros Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. YARTEMLEA gross revenue increased 190% sequentially to $32.2 million in the second quarter, producing $4.1 million of company-wide operating cash flow, adjusted net income, and a slight operating profit. The company also repurchased $30.5 million of 2029 Notes, but withheld revenue guidance, expects higher third-quarter operating expenses, and faces a negative CHMP opinion under re-examination.
- + YARTEMLEA gross revenue rose 190% sequentially to $32.2 million, with $28.5 million net revenue
- + The company generated $4.1 million of operating cash flow and returned to operating profitability
- + Adjusted results improved to $1.8 million of net income from a $17.1 million loss
- + The company reduced 2029 Notes principal by 43% and eliminated $8.6 million of future interest payments
- + Management reiterated its expectation of company-wide positive cash flow by mid-2027
- − The company is not providing YARTEMLEA revenue guidance
- − Third-quarter operating expenses are expected to increase, led by OMS805 and YARTEMLEA launch investment
- − CHMP issued a negative opinion on the European marketing application, which is under re-examination
- − A $1.9 million loss was recorded on the first tranche of 2029 Note repurchases
- − Third-quarter interest and other income is expected to decline because the inventory reimbursement will not recur
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash provided by operations | $4.1M | Q2 2026 | — |
| Non-GAAP adjusted net income non-GAAP | $1.8M | Q2 2026 | — |
| Outstanding principal amount of 2029 Notes remaining | $40.3M | Q2 2026 | — |
| Shares issuable upon conversion of 2029 Notes (remaining) | 6.5M | Q2 2026 | — |
| Shares of common stock repurchased | 0.8M | Six months ended June 30, 2026 | — |
| YARTEMLEA gross revenues | $32.2M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OMER
this stock
Omeros Corp
|
$1.45B | +10.8% | -53.9% | — | 17.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OMER | -8.2% | +1.6% | +59.9% | +1.3% | +10.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -7.5% | +1.4% | +47.7% | +1.9% | -1.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.